An elevated blood glucose concentration >8.3 mmol/L (>150 mg/dL) occurs frequently in VLBW infants, especially during the first days after birth. 1
Diagnosis
The following infants should be screened for hyper-(and hypo-) glycaemia:
Infants born <35 weeks gestation Infants receiving IV fluids or TPN Sick infants Infants with glycosuria Screening blood glucose level = SBGL: performed on Accu-Check® Advantage Meter. 14, 15 Formal blood glucose level = FBGL: to confirm high SBGL before commencing treatment. Performed in laboratory on serum specimen preferably using calcium oxalate tubes Â-note: use of lithium heparin tubes with delay in assay results in falsely low BGL. Repeated FBGL are not necessary for monitoring of treatment.
Definitions:
Hyperglycaemia that has been associated with adverse outcomes in observational studies is defined as BGL >8.3 mmol/L. Trials that reported treatment of hyperglycemia was associated with improved non-protein energy intake and short term growth most commonly enrolled infants with a persistent BGL 8.9 mmol/l 16 or >9.9 mmol/L. 17 
Treatment Prevention:
Glucose administration to preterm infants should start at 4-8mg/kg/min (or 5.8g/kg/day to 11.5g/kg/day), 18 and should not exceed 13mg/kg/min (or 18g/kg/day) for full term neonates as this tends to induce net lipogenesis. Premature infants are often relatively intolerant with glycosuria (not always with an osmotic diuresis).
Systematic review 19 of trials of early insulin infusion for prevention of neonatal hyperglycemia found that use of an insulin infusion reduced hyperglycemia but increased death before 28 days and increased the risk of hypoglycemia. The reduction in hyperglycemia was not accompanied by significant effects on major morbidities; effects on neurodevelopment are awaited. 19 
Treatment:
Systematic review of trials of insulin infusion for treatment of neonatal hyperglycemia found that use of an insulin infusion obviates the need to decrease the concentration of dextrose prescribed, and optimised the utilisation of calories by the infant resulting in significant increases in non-protein energy intake, glucose intake, and short-term weight gain. 20 However, Insulin infusion had no significant effect on death, severe intraventricular hemorrhage, retinopathy of prematurity, bacterial sepsis, fungal sepsis, or necrotizing enterocolitis; effects on other major morbidities were not assessed. These trials did not report an excess of hypoglycaemia, possibly due to the more liberal target BGLs (4.4 Â-9.9 mmol/L 17 and 5.5-9.9 mmol/L 16 ).
What we do at RPA: Consider insulin infusion (see insulin Â-hyperglycemia policy), AND Change back to TPN with 10% Dextrose. The goal is now improved growth.
Target BGL = 5.5 -9.9 mmol/L 16 Other considerations:
Initially BGL should be monitored closely when infusion is first commenced -at 30 minutes and then at 1 hour post infusion. Once stabilised BGL may be measured 4-6th hourly. Check BGL more frequently if maintenance solution, and/or medication mixed with glucose and/or an insulin infusion is disrupted or rate of administration is changed.
Do not flush insulin infusion -infant will receive a bolus dose Change infusion 24th hourly.
